Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027867 · ClinicalTrials.gov registry record · Phase 2
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Phase 2 study, sponsored by Kartos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05027867: Clinical Trial Phase 2 study, sponsored by Kartos Therapeutics.
NCT05027867 is a Phase 2 study that was terminated before completion, run by Kartos Therapeutics. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05027867, a Phase 2 study, was terminated before completion, sponsored by Kartos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.
Primary Outcome
The proportion of subjects achieving partial response or better per RECIST 1.1
Interventions
- DRUG KRT-232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 2 |
Why NCT05027867 stopped before completion
NCT05027867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which KRT-232 is the first listed.
NCT05027867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05027867 about?
NCT05027867 is a clinical study titled "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer". This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue t...
What is the current status of trial NCT05027867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-12-06. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT05027867?
The interventions under investigation include: KRT-232 (DRUG).
Who is sponsoring clinical trial NCT05027867?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05027867's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI